论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zhao D, Hou H, Zhang X
Received 25 April 2018
Accepted for publication 7 June 2018
Published 19 July 2018 Volume 2018:11 Pages 4137—4147
DOI https://doi.org/10.2147/OTT.S172305
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Takuya Aoki
Abstract: With the investigation of molecular targets, many agents, such as
trastuzumab and ramucirumab, have attained a positive outcome in oncotherapy.
Vascular endothelial growth factor (VEGF) is considered a potent factor in
angiogenesis and plays an important role in the growth of tumors. Moreover,
both VEGF and its receptor are usually excessively expressed in solid tumors
and could be hopeful targets for the treatment of neoplasms. Apatinib (YN968D1)
is an oral small-molecule tyrosine kinase inhibitor of VEGFR-2. By inhibiting
several signaling transduction pathways, it restrains angiogenesis and
subsequently controls tumorigenesis. According to current studies, apatinib
shows promising application in various solid tumors as a post-second- and post-third-line
treatment. It could significantly improve the median overall survival and
progression-free survival of patients with tolerated adverse reactions. This
paper aims to summarize the recent research on apatinib including the
mechanism, pharmacokinetics, trials, adverse reactions, and prospect as a
treatment.
Keywords: VEGF, VEGFR-2,
apatinib, angiogenesis, solid tumors, gastric cancer